SABCS: Long-Term Benefits for Zoledronic Acid in Breast Cancer

Share this content:
SABCS: Long-Term Benefits for Zoledronic Acid in Breast Cancer
SABCS: Long-Term Benefits for Zoledronic Acid in Breast Cancer

(HealthDay News) - In the long-term, adjuvant zoledronic acid (ZOL) is associated with a significant reduction in disease-free survival (DFS) events and death in premenopausal women with endocrine-receptor positive early-stage breast cancer; and for postmenopausal women with hormone receptor-positive early breast cancer, immediate treatment with zoledronic acid is associated with a reduced risk of DFS events, according to two studies presented at the 2011 San Antonio Breast Cancer Symposium.

Michael Gnant, MD (of the Medical University of Vienna in Austria) and colleagues investigated the long-term effect of adjuvant zoledronic acid for premenopausal patients with endocrine-responsive early stage breast cancer. At a median follow-up of 76 months, compared with patients not receiving zoledronic acid, those patients receiving zoledronic acid treatment had a significant reduction in the risk of DFS events (HR, 0.73) and death (HR, 0.59).

Richard de Boer, MD (of the Royal Melbourne Hospital in Australia) and colleagues compared the benefit of immediate (IMZOL) or delayed (DZOL) treatment with zoledronic acid, for 1,065 postmenopausal women with hormone receptor-positive early breast cancer. At 60 months of follow-up, there was a significant reduction in the risk of a DFS event with immediate zoledronic acid treatment versus delayed zoledronic acid treatment (HR, 0.66). For women who were postmenopausal for more than five years, or were older than 60 at the study entry, immediate zoledronic acid treatment was associated with significantly improved DFS and prolonged overall survival versus delayed zoledronic acid treatment (HR, 0.63 and 0.50, respectively).

"Long-term follow-up in [the] Zometa-Femara Adjuvant Synergy Trial confirms the overall survival benefits of adding zoledronic acid (4mg q6mo) to adjuvant letrozole therapy for early breast cancer," de Boer and colleagues write.

Press Release - Gnant
Press Release - de Boer
More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs